STXBP1 Encephalopathy — Preclinical Gene Therapy Program

Executive Summary

STXBP1 encephalopathy (also known as Early Infantile Epileptic Encephalopathy 5, EIEE5, or STXBP1-E) is a devastating neurodevelopmental disorder caused by pathogenic variants in the [STXBP1 gene](/genes/stxbp1), which encodes Munc18-1 — a critical synaptic protein required for neurotransmitter release. Unlike many genetic epilepsies, there are currently no disease-modifying therapies specifically targeting the underlying genetic cause. Several academic groups are actively developing AAV-based gene therapy approaches for STXBP1, representing a potential breakthrough for this devastating condition.

Program Overview

| Parameter | Value |
|-----------|-------|
| Target Indication | STXBP1 Encephalopathy (EIEE5) |
| Gene | STXBP1 |
| Gene Size | ~2 kb coding sequence |
| Vector | AAV (serotype TBD) |
| Delivery Route | Intrathecal or intracisterna magna (under investigation) |
| Development Stage | Preclinical (research/lead optimization) |
| Lead Groups | Multiple academic laboratories |

Disease Context: STXBP1 Encephalopathy

Clinical Presentation

[STXBP1](/genes/stxbp1) encephalopathy is one of the most common genetic epileptic encephalopathies, accounting for approximately 5-10% of EIEE cases. Key clinical features include:

Executive Summary

STXBP1 encephalopathy (also known as Early Infantile Epileptic Encephalopathy 5, EIEE5, or STXBP1-E) is a devastating neurodevelopmental disorder caused by pathogenic variants in the [STXBP1 gene](/genes/stxbp1), which encodes Munc18-1 — a critical synaptic protein required for neurotransmitter release. Unlike many genetic epilepsies, there are currently no disease-modifying therapies specifically targeting the underlying genetic cause. Several academic groups are actively developing AAV-based gene therapy approaches for STXBP1, representing a potential breakthrough for this devastating condition.

Program Overview

| Parameter | Value |
|-----------|-------|
| Target Indication | STXBP1 Encephalopathy (EIEE5) |
| Gene | STXBP1 |
| Gene Size | ~2 kb coding sequence |
| Vector | AAV (serotype TBD) |
| Delivery Route | Intrathecal or intracisterna magna (under investigation) |
| Development Stage | Preclinical (research/lead optimization) |
| Lead Groups | Multiple academic laboratories |

Disease Context: STXBP1 Encephalopathy

Clinical Presentation

[STXBP1](/genes/stxbp1) encephalopathy is one of the most common genetic epileptic encephalopathies, accounting for approximately 5-10% of EIEE cases. Key clinical features include:

• Onset: First year of life (typically 1-12 months, median ~6 months)
• Seizure types:
• Infantile spasms (West syndrome)
• Focal seizures
• Tonic-clonic seizures
• Myoclonic seizures
• Early myoclonic encephalopathy
• EEG findings: Burst-suppression pattern in ~50% of cases
• Development: Normal at birth, followed by developmental stagnation and regression
• Core symptoms:
• Severe intellectual disability
• Movement disorders (ataxia, dystonia, choreoathetosis)
• Hypotonia
• Microcephaly in many cases
• Prognosis: Severe, with ongoing seizures and significant developmental impairment

Epidemiology

• Incidence: ~1 in 100,000-150,000 live births
• Prevalence: Estimated 500-1,000 patients in the US
• Inheritance: Autosomal dominant (de novo variants common)
• Gender distribution: Slight female predominance due to reduced male viability

Molecular Mechanism

STXBP1 encodes Munc18-1, a synaptic protein essential for neurotransmitter release:

Gene Therapy Approach

Vector Design

| Component | Design Consideration |
|-----------|-----------------|
| Promoter | Synapsin or CamKIIa for neuron-specific expression |
| Transgene | Full-length human STXBP1 coding sequence |
| Introns | Synthetic intron for proper expression |
| PolyA | bGH or SV40 polyA signal |
| Serotype | AAV9 or AAV-PHP.eB for CNS penetration |

Preclinical Data Requirements

1. Proof-of-Concept Studies

| Study | Model | Readout | Status |
|-------|-------|--------|--------|
| AAV-STXBP1 in Stxbp1+/− mice | Heterozygous mouse model | Seizure frequency, behavior | Ongoing |
| AAV-STXBP1 in iPSC-derived neurons | Human neurons | Electrophysiology | Research |
| Dose-ranging study | Wild-type mice | Biodistribution, expression | Completed |

2. IND-Enabling Studies Required

| Study | Purpose | Timeline |
|-------|--------|---------|
| GLP toxicology (rodent) | Safety assessment | Required |
| GLP toxicology (NHP) | Safety in relevant species | Required |
| Biodistribution | Tissue distribution | Required |
| Driver line safety | Inclusion in CTA | Required |

Key Challenges

| Challenge | Impact | Mitigation Strategy |
|-----------|--------|---------------|
| Broad CNS distribution | STXBP1 expressed throughout brain | Multiple delivery routes under investigation |
| Timing | Critical developmental window | Early intervention target |
| GABAergic targeting | Need inhibitory neuron expression | Promoter selection |
| Phenotypic heterogeneity | Variable severity | Patient stratification |

Clinical Trial Design Considerations

Trial Population

• Inclusion criteria: Genetically confirmed STXBP1 pathogenic variant
• Age: Pediatrics (0-18 years), with prioritization of early intervention
• Seizure history: Evidence of ongoing seizures or developmental regression

Endpoint Selection

| Endpoint Category | Specific Endpoint | Rationale |
|----------------|----------------|-----------|
| Primary | Seizure frequency (parent diary) | Direct disease manifestation |
| Secondary | Developmental assessment (Bayley-III/Vineland-3) | Key comorbidity |
| Secondary | CGI-C | Clinical global impression |
| Exploratory | EEG background normalization | Biomarker of effect |
| Exploratory | Motor function (PDMS-2) | Movement disorder assessment |

Regulatory Considerations

• Orphan drug designation: Likely eligible (premarket)
• Rare pediatric disease PRV: Available if approved
• Accelerated approval pathway: May be possible with biomarker
• Natural history as comparator: Critical for regulatory discussions

Competitive Landscape

Other Gene Therapy Programs for STXBP1

| Entity | Status | Approach | Differentiation |
|--------|--------|----------|--------------|
| Academic (US) | Research | AAV-STXBP1 | Focus on delivery optimization |
| Academic (EU) | Research | AAV-STXBP1 | Focus on cell-type targeting |

Adjacent Programs

While no other companies have announced clinical STXBP1 programs, the following may inform development:

• SMA (SMN1): Zolgensma — precedent for CNS gene therapy
• SCN1A (Dravet): STK-001 ASO and ETX101 — similar regulatory pathway
• UBE3A (Angelman): GTX-102 ASO learnings

Key Open Questions

References

Cross-Links

• [STXBP1 Gene Page](/genes/stxbp1)](/genes)
• [AAV Gene Therapy for Neurodevelopmental Epilepsy](/therapeutics/aav-gene-therapy-neurodevelopmental-epilepsy)](/therapeutics)
• [AAV Vectors](/technologies/aav-vectors)](/technologies)
• [Gene Therapy Overview](/technologies/gene-therapy)](/technologies)
• [STK-001 Dravet Phase 1/2](/clinical-trials/stk001-dravet-syndrome-phase-1-2)
• [ETX101 Dravet Gene Activation](/clinical-trials/etx101-encoded-therapeutics-dravet-syndrome)